» Articles » PMID: 38586339

Curcumin Simultaneously Improves Mitochondrial Dynamics and Myocardial Cell Bioenergy After Sepsis Via the SIRT1-DRP1/PGC-1α Pathway

Overview
Journal Heliyon
Specialty Social Sciences
Date 2024 Apr 8
PMID 38586339
Authors
Affiliations
Soon will be listed here.
Abstract

Septic cardiomyopathy (SCM) is associated with an imbalance in mitochondrial quality and high mortality rates, with no effective treatment developed to date. Curcumin provides antioxidant, anti-inflammatory, cardiovascular, and mitochondrial protection. However, curcumin has not been confirmed to improve cardiac dysfunction in sepsis. We hypothesized that curcumin can reduce abnormal inflammatory responses by improving mitochondrial function as a novel mechanism to improve SCM. To explore this hypothesis, we used an male C57BL/6 mouse sepsis model and an model of lipopolysaccharide-stimulated HL-1 cells. The effects of curcumin on sepsis-induced cardiac dysfunction, inflammatory responses, and mitochondrial quality of cardiac cells were observed using quantitative polymerase chain reaction, western blotting, echocardiography, and transmission electron microscopy. Curcumin activated sirtuin 1 (SIRT1); increased expression of the mitochondrial biogenesis-related genes , , and reduced dynamin-related protein 1 translocation from the cytoplasm to mitochondria; and restored the mitochondrial morphology and function in cardiac cells. Accordingly, curcumin protected heart function after septic shock and alleviated the effects of SCM. SIRT1 knockdown reversed the protective effects of curcumin on mitochondria. Therefore, curcumin promotes mitochondrial biogenesis and inhibits mitochondrial fragmentation by activating SIRT1, thereby improving the mitochondrial quality and reducing oxidative stress in cardiomyocytes and sepsis-induced cardiac dysfunction. These findings provide new evidence supporting the use of curcumin to treat SCM.

Citing Articles

Insights Into the Therapeutic Potential of SIRT1-modifying Compounds for Alzheimer's Disease: A Focus on Molecular Mechanisms.

AlHayani D, Kubaev A, Uthirapathy S, Mandaliya V, Ballal S, Kalia R J Mol Neurosci. 2025; 75(1):29.

PMID: 40000535 DOI: 10.1007/s12031-025-02324-9.


Sepsis-induced cardiac dysfunction: mitochondria and energy metabolism.

Yu X, Gao J, Zhang C Intensive Care Med Exp. 2025; 13(1):20.

PMID: 39966268 PMC: 11836259. DOI: 10.1186/s40635-025-00728-w.


Supplementation with aspalathin and sulforaphane protects cultured cardiac cells against dyslipidemia-associated oxidative damage.

Mthembu S, Mazibuko-Mbeje S, Silvestri S, Orlando P, Nkambule B, Muller C Metabol Open. 2025; 25:100346.

PMID: 39882383 PMC: 11774938. DOI: 10.1016/j.metop.2025.100346.


Mechanisms of mitochondrial damage-associated molecular patterns associated with inflammatory response in cardiovascular diseases.

Guan X, Li H, Zhang L, Zhi H Inflamm Res. 2025; 74(1):18.

PMID: 39806203 DOI: 10.1007/s00011-025-01993-x.


Curcumin: A Golden Approach to Healthy Aging: A Systematic Review of the Evidence.

Nunes Y, Mendes N, de Lima E, Chehadi A, Lamas C, Haber J Nutrients. 2024; 16(16).

PMID: 39203857 PMC: 11357524. DOI: 10.3390/nu16162721.


References
1.
Saeidinia A, Keihanian F, Butler A, Khameneh Bagheri R, Atkin S, Sahebkar A . Curcumin in heart failure: A choice for complementary therapy?. Pharmacol Res. 2018; 131:112-119. DOI: 10.1016/j.phrs.2018.03.009. View

2.
Merx M, Weber C . Sepsis and the heart. Circulation. 2007; 116(7):793-802. DOI: 10.1161/CIRCULATIONAHA.106.678359. View

3.
Li R, Li X, Zhao J, Meng F, Yao C, Bao E . Mitochondrial STAT3 exacerbates LPS-induced sepsis by driving CPT1a-mediated fatty acid oxidation. Theranostics. 2022; 12(2):976-998. PMC: 8692896. DOI: 10.7150/thno.63751. View

4.
Aguiar C, Rocha-Franco J, Sousa P, Santos A, Ladeira M, Rocha-Resende C . Succinate causes pathological cardiomyocyte hypertrophy through GPR91 activation. Cell Commun Signal. 2014; 12:78. PMC: 4296677. DOI: 10.1186/s12964-014-0078-2. View

5.
Lin Y, Xu Y, Zhang Z . Sepsis-Induced Myocardial Dysfunction (SIMD): the Pathophysiological Mechanisms and Therapeutic Strategies Targeting Mitochondria. Inflammation. 2020; 43(4):1184-1200. DOI: 10.1007/s10753-020-01233-w. View